Verrica Pharmaceuticals Inc. (VRCA)
| Market Cap | 287.62M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -37.35M |
| Shares Out | 24.99M |
| EPS (ttm) | -1.50 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 20 |
| Last Price | $11.63 |
| Previous Close | $11.12 |
| Change ($) | 0.51 |
| Change (%) | 4.54% |
| Day's Open | 11.13 |
| Day's Range | 11.13 - 11.81 |
| Day's Volume | 51,243 |
| 52-Week Range | 6.16 - 16.86 |
- In new post hoc analyses of the Phase 3 molluscum trials segmenting molluscum lesions by body region and study visit, the percentage of participants with complete clearance of all baseline a...
WEST CHESTER, Pa., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requir...
- Verrica reaffirms expectation to resubmit its New Drug Application for VP-102 for the treatment of molluscum in the first quarter of 2021 - - Verrica reaffirms expectation to resubmit its Ne...
WEST CHESTER, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requir...
- 35 % of subjects treated with VP-102 achieved complete clearance of all treatable genital warts vs 2. 4 % for vehicle (p=0.0001) -
- Verrica completes Type A meeting and expects to resubmit its New Drug Application for VP-102 for the treatment of molluscum in the first quarter of 2021 -
WEST CHESTER, Pa., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases req...
NEW YORK, Sept. 14, 2020 /PRNewswire/ --Pomerantz LLP is investigating claims on behalf of investors of Verrica Pharmaceuticals Inc.
NEW YORK, Sept. 14, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Verrica Pharmaceuticals...
LOS ANGELES--(BUSINESS WIRE)---- $VRCA #VRCA--DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Verrica Pharmaceuticals Inc.
LOS ANGELES--(BUSINESS WIRE)---- $VRCA #classaction--The Law Offices of Frank R. Cruz reminds investors of the upcoming September 14, 2020 deadline to file a lead plaintiff motion in the class...
Los Angeles, California--(Newsfile Corp. - September 11, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Ver...
New York, New York--(Newsfile Corp. - September 10, 2020) - Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Verrica Pharmaceuticals Inc.
BENSALEM, Pa., Sept. 10, 2020 /PRNewswire/ -- Law Offices of Howard G.
Los Angeles, California--(Newsfile Corp. - September 10, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Ver...
LOS ANGELES, Sept. 9, 2020 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming September 14, 2020 deadline to file a lead plaintiff motion in the class action...
Los Angeles, California--(Newsfile Corp. - September 9, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Verri...
WEST CHESTER, Pa., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases req...
New York, New York--(Newsfile Corp. - September 8, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Verrica Pharmaceuticals Inc.
Los Angeles, California--(Newsfile Corp. - September 8, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Verri...
New York, New York--(Newsfile Corp. - August 25, 2020) - Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requ...
- Company intends to request a Type A meeting with FDA during the third quarter of 2020 to discuss next steps for resubmission of an NDA for VP-102 following Complete Response Letter -
Verrica Pharmaceuticals: The Fundamentals Aren't So Clear, But The Stock Chart May Be Telling Us Something
New York, New York--(Newsfile Corp. - July 24, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Verrica Pharmaceuticals Inc.
– Leading pediatric dermatologist brings significant expertise in the treatment of skin diseases to help inform development of the Company’s product candidates –
– Dr. Gary Goldenberg appointed Chief Medical Officer; Dr. Brad Catalone assumes the role of Head of Drug Development –
New York, New York--(Newsfile Corp. - July 22, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Verrica Pharmaceuticals Inc.
New York, New York--(Newsfile Corp. - July 20, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Verrica Pharmaceuticals Inc.
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Verrica Pharmaceutical...
Los Angeles, California--(Newsfile Corp. - July 17, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Verrica P...
SAN DIEGO & WEST CHESTER, Pa.--(BUSINESS WIRE)---- $VRCA #ClassAction--Shareholder rights law firm Robbins LLP announces that a purchaser of Verrica Pharmaceuticals Inc.
LOS ANGELES--(BUSINESS WIRE)---- $VRCA #VRCA--SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Verrica Pharmaceuticals Inc.
LOS ANGELES--(BUSINESS WIRE)---- $VRCA #VRCA--SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Verrica Pharmaceuticals Inc.
New York, New York--(Newsfile Corp. - July 15, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Verrica Pharmaceuticals Inc. ("V...
BENSALEM, Pa.--(BUSINESS WIRE)---- $VRCA #classaction--Law Offices of Howard G.
NEW YORK--(BUSINESS WIRE)-- #VRCA--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States D...
The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against Verrica Pharmaceuticals Inc.
LOS ANGELES--(BUSINESS WIRE)---- $VRCA #classaction--The Law Offices of Frank R. Cruz announces that it has filed a class action lawsuit in the United States District Court for the Eastern Dis...
– Complete Response Letter Requests Additional Chemistry, Manufacturing, and Controls (CMC) and Human Factors Information –
Verrica (VRCA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
LOS ANGELES--(BUSINESS WIRE)---- $VRCA #classaction--The Law Offices of Frank R. Cruz continues its investigation on behalf of Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ...
SAN DIEGO & WEST CHESTER, Pa.--(BUSINESS WIRE)---- $VRCA #ClassAction--Shareholder rights law firm Robbins LLP announces it is investigating whether certain officers and directors of Verrica P...
NEW YORK, July 2, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verrica Pharmaceuticals Inc. ("Ve...
LOS ANGELES--(BUSINESS WIRE)---- $VRCA #classaction--The Law Offices of Frank R. Cruz announces an investigation on behalf of Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ:...
Verrica Pharmaceuticals (NASDAQ: VRCA) shares are trading lower on Tuesday. The company received a letter from the FDA regarding its VP-102 NDA indicating there are deficiencies that preclude ...
WEST CHESTER, Pa., June 29, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for viral skin disease...
- Pre-specified exploratory analysis showed VP-102 brought about a statistically significant percentage of patients with complete molluscum lesion clearance across all lesion count quartiles c...
– Global biopharmaceutical industry veteran brings significant commercial expertise and business acumen to help advance the Company’s medical dermatology portfolio –
WEST CHESTER, Pa., March 11, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for viral skin diseas...
– Gerard DiGirolamo joins as Vice President, Sales, and Sheila Kennedy joins as Vice President, Marketing –
About VRCA
Verrica Pharmaceuticals, a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The company's lead product candidate include VP-102 that is in phase III clinical trial for the treatment of molluscum contagiosum; in phase II clinical trial for the treatment of common warts; and completed phase I clinical trial for the treatment of Genital warts. It is also developing cantharidin-based product candidate, VP-103 for the treatment of plantar warts. The company has a license agreemen... [Read more...]
| Industry Biotechnology | IPO Date Jun 15, 2018 |
| CEO Ted White | Employees 17 |
| Stock Exchange NASDAQ | Ticker Symbol VRCA |
Analyst Forecasts
According to 5 analysts, the average rating for VRCA stock is "Strong Buy." The 12-month stock price forecast is 18.50, which is an increase of 59.14% from the latest price.